^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LAG3 expression

    i
    Other names: LAG3, Lymphocyte Activating 3, Lymphocyte Activation Gene 3 Protein, Lymphocyte-Activation Gene 3, CD223 Antigen, CD223, LAG-3, FDC
    Entrez ID:
    3902
    Related biomarkers:
    Expression
    Mutation
    Others
    Apply
    Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting (NCT03743766)
    Phase 2
    John Kirkwood
    Completed
    Last update posted :
    09/25/2024
    Initiation :
    03/29/2019
    Primary completion :
    07/03/2024
    Completion :
    07/03/2024
    PD-1 • LAG3
    |
    PD-1 expression • LAG3 expression
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer (NCT02923180)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    02/14/2017
    Primary completion :
    08/11/2020
    Completion :
    12/01/2024
    AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1
    |
    CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression
    |
    enoblituzumab (MGA271)
    Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (IMAGINE) (NCT04062656)
    Phase 2
    University Hospital, Essen
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    09/26/2019
    Primary completion :
    03/01/2024
    Completion :
    06/01/2025
    LAG3
    |
    LAG3 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • relatlimab (BMS-986016)
    A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients (NCT05787613)
    Phase 2
    Shanghai Henlius Biotech
    Recruiting
    Last update posted :
    02/22/2024
    Initiation :
    07/10/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2027
    PD-L1 • ROS1 • LAG3
    |
    PD-L1 expression • ROS1 rearrangement • LAG3 expression
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Hetronifly (serplulimab) • HLX26
    LAG3 Expression in Triple Negative Breast Cancer (NCT06259162)
    Phase N/A
    Samsung Medical Center
    Recruiting
    Last update posted :
    02/14/2024
    Initiation :
    11/18/2022
    Primary completion :
    07/01/2025
    Completion :
    12/31/2027
    LAG3
    |
    LAG3 expression
    Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (NCT04326257)
    Phase 2
    Dan Zandberg
    Active, not recruiting
    Last update posted :
    02/07/2024
    Initiation :
    06/05/2020
    Primary completion :
    08/12/2023
    Completion :
    08/12/2024
    LAG3 • CTLA4
    |
    LAG3 expression • CTLA4 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (NCT03219268)
    Phase 1
    MacroGenics
    Completed
    Last update posted :
    12/21/2023
    Initiation :
    08/18/2017
    Primary completion :
    02/08/2023
    Completion :
    02/08/2023
    PD-L1 • PD-1 • LAG3
    |
    PD-L1 expression • HER-2 positive • LAG3 expression • MHC-II expression
    |
    Margenza (margetuximab-cmkb) • tebotelimab (MGD013)
    Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy (NCT05020912)
    Phase 2
    Case Comprehensive Cancer Center
    Recruiting
    Last update posted :
    11/09/2023
    Initiation :
    12/13/2021
    Primary completion :
    09/01/2027
    Completion :
    12/01/2027
    PD-L1 • CD8 • LAG3 • CTLA4 • HAVCR2 • IL2RA • CD33 • TIGIT • CD4 • IL7R • NCAM1 • S100A9 • FOXP3
    |
    LAG3 expression
    89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) (NCT04566978)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    10/17/2023
    Initiation :
    09/11/2020
    Primary completion :
    09/11/2025
    Completion :
    09/11/2025
    LAG3
    |
    LAG3 expression
    |
    fianlimab (REGN3767)
    Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC (MIMOSA) (NCT04368468)
    Phase N/A
    Institut Claudius Regaud
    Completed
    Last update posted :
    12/23/2022
    Initiation :
    06/15/2020
    Primary completion :
    12/15/2020
    Completion :
    01/31/2021
    PD-L1 • LAG3 • HAVCR2
    |
    PD-L1 expression • LAG3 expression • HAVCR2 expression
    PET Imaging of LAG-3 Expression (NCT05346276)
    Phase N/A
    The First Affiliated Hospital of Xiamen University
    Recruiting
    Last update posted :
    05/12/2022
    Initiation :
    04/06/2022
    Primary completion :
    05/01/2024
    Completion :
    05/01/2024
    LAG3
    |
    LAG3 expression